Increased Abundance of Clostridium and Fusobacterium in Gastric Microbiota of Patients with Gastric Cancer in Taiwan

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Hsieh, Yung Yu ^a,b   Tung, Shui Yi ^a,b   Pan, Hung Yu ^c   Yen, Chih Wei ^a,b   Xu, Huang Wei ^a,b   Lin, Ying Jhen ^a   Deng, Yi Fang ^a   Hsu, Wan Ting ^d   Wu, Cheng Shyong ^a,b   Li, Chin ^d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

RNA 16S;

ADULT; AGED; CANCER STAGING; CLOSTRIDIUM; CLOSTRIDIUM INFECTION; COMPLICATION; FEMALE; FUSOBACTERIUM; FUSOBACTERIUM INFECTION; GENETICS; HUMAN; MALE; METAPLASIA; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; STOMACH MUCOSA; STOMACH TUMOR; TAIWAN; YOUNG ADULT;

ADULT; AGED; CLOSTRIDIUM; CLOSTRIDIUM INFECTIONS; FEMALE; FUSOBACTERIUM; FUSOBACTERIUM INFECTIONS; GASTRIC MUCOSA; HUMANS; MALE; METAPLASIA; MIDDLE AGED; NEOPLASM STAGING; RNA, RIBOSOMAL, 16S; STOMACH NEOPLASMS; TAIWAN; YOUNG ADULT;

EID: 85040514150     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-18596-0     Document Type: Article

References (48)

1. Sekirov, I., Russell, S. L., Antunes, L. C. & Finlay, B. B. Gut microbiota in health and disease. Physiol. Rev. 90, 859-904, https://doi.org/10.1152/physrev.00045.2009 (2010).
2. Festi, D. et al. Gut microbiota and its pathophysiology in disease paradigms. Dig. Dis. 29, 518524, https://doi.org/10.1159/000332975 (2011).
3. Yamamoto, M. & Matsumoto, S. Gut microbiota and colorectal cancer. Genes Environ. 38, 11, https://doi.org/10.1186/s41021-016-0038-8 (2016).
4. Schulz, C., Schutte, K. & Malfertheiner, P. Helicobacter pylori and other gastric microbiota in gastroduodenal pathologies. Dig. Dis. 34, 210-216, https://doi.org/10.1159/000443353 (2016).
5. Servetas, S. L., Bridge, D. R. & Merrell, D. S. Molecular mechanisms of gastric cancer initiation and progression by Helicobacter pylori. Curr. Opin. Infect. Dis. 29, 304-310, https://doi.org/10.1097/QCO.0000000000000248 (2016).
6. Flanagan, L. et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur. J. Clin. Microbiol. Infect. Dis. 33, 1381-1390, https://doi.org/10.1007/s10096-014-2081-3 (2014).
7. Fukugaiti, M. H. et al. High occurrence of Fusobacterium nucleatum and Clostridium difficile in the intestinal microbiota of colorectal carcinoma patients. Braz. J. Microbiol. 46, 1135-1140, https://doi.org/10.1590/S1517-838246420140665 (2015).
8. Li, Y. Y. et al. Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J. Gastroenterol. 22, 3227-3233, https://doi.org/10.3748/wjg.v22.i11.3227 (2016).
9. Ianiro, G., Molina-Infante, J. & Gasbarrini, A. Gastric microbiota. Helicobacter 20(Suppl 1), 68-71, https://doi.org/10.1111/hel.12260 (2015).
10. Hutton, M. L. et al. Helicobacter pylori exploits cholesterol-rich microdomains for induction of NF-κB-dependent responses and peptidoglycan delivery in epithelial cells. Infect. Immun. 78, 4523-4531, https://doi.org/10.1128/IAI.00439-10 (2010).
11. Khan, S., Karim, A. & Iqbal, S. Helicobacter urease: niche construction at the single molecule level. J. Biosci. 34, 503-511 (2009).
12. Viala, J. et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat. Immunol. 5, 1166-1174, https://doi.org/10.1038/ni1131 (2004).
13. Tegtmeyer, N., Wessler, S. & Backert, S. Role of the cag-pathogenicity island encoded type IV secretion system in Helicobacter pylori pathogenesis. FEBS J. 278, 1190-1202, https://doi.org/10.1111/j.1742-4658.2011.08035.x (2011).
14. Wu, J., Xu, S. & Zhu, Y. Helicobacter pylori CagA: A critical destroyer of the gastric epithelial barrier. Dig. Dis. Sci. 58, 1830-1837, https://doi.org/10.1007/s10620-013-2589-x (2013).
15. Tohidpour, A. CagA-mediated pathogenesis of Helicobacter pylori. Microb. Pathog. 93, 44-55, https://doi.org/10.1016/j.micpath.2016.01.005 (2016).
16. Sycuro, L. K. et al. Multiple peptidoglycan modification networks modulate Helicobacter pylori's cell shape, motility, and colonization potential. PLOS Pathog. 8, e1002603, https://doi.org/10.1371/journal.ppat.1002603 (2012).
17. Peleteiro, B., Bastos, A., Ferro, A. & Lunet, N. Prevalence of Helicobacter pylori infection worldwide: A systematic review of studies with national coverage. Dig. Dis. Sci. 59, 1698-1709, https://doi.org/10.1007/s10620-014-3063-0 (2014).
18. Hooi, J. K. Y. et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-Analysis. Gastroenterology, https://doi.org/10.1053/j.gastro.2017.04.022 (2017).
19. Aviles-Jimenez, F., Vazquez-Jimenez, F., Medrano-Guzman, R., Mantilla, A. & Torres, J. Stomach microbiota composition varies between patients with non-Atrophic gastritis and patients with intestinal type of gastric cancer. Sci. Rep. 4, 4202, https://doi.org/10.1038/srep04202 (2014).
20. Eun, C. S. et al. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter 19, 407-416, https://doi.org/10.1111/hel.12145 (2014).
21. Wang, L. et al. Bacterial overgrowth and diversification of microbiota in gastric cancer. Eur. J. Gastroenterol. Hepatol. 28, 261-266, https://doi.org/10.1097/MEG.0000000000000542 (2016).
22. Dias-Jacome, E., Libanio, D., Borges-Canha, M., Galaghar, A. & Pimentel-Nunes, P. Gastric microbiota and carcinogenesis: The role of non-Helicobacter pylori bacteria-A systematic review. Rev. Esp. Enferm. Dig. 108, 530-540, https://doi.org/10.17235/reed.2016.4261/2016 (2016).
23. Amir, I., Konikoff, F. M., Oppenheim, M., Gophna, U. & Half, E. E. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. Environ. Microbiol. 16, 2905-2914, https://doi.org/10.1111/1462-2920.12285 (2014).
24. Coenye, T. et al. Burkholderia fungorum sp. nov. and Burkholderi acaledonica sp. nov., two new species isolated from the environment, animals and human clinical samples. Int. J. Syst. Evol. Microbiol. 51, 1099-1107, https://doi.org/10.1099/00207713-51-3-1099 (2001).
25. Gerrits, G. P., Klaassen, C., Coenye, T., Vandamme, P. & Meis, J. F. Burkholderia fungorum septicemia. Emerg. Infect. Dis. 11, 1115-1117, https://doi.org/10.3201/eid1107.041290 (2005).
26. De Mauri, A. et al. Leclercia adecarboxylata and catheter-related bacteraemia: review of the literature and outcome with regard to catheters and patients. J. Med. Microbiol. 62, 1620-1623, https://doi.org/10.1099/jmm.0.059535-0 (2013).
27. Keren, Y. et al. Is Leclercia adecarboxylata a new and unfamiliar marine pathogen? J. Clin. Microbiol. 52, 1775-1776, https://doi.org/10.1128/JCM.03239-13 (2014).
28. Nosho, K. et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J. Gastroenterol. 22, 557-566, https://doi.org/10.3748/wjg.v22.i2.557 (2016).
29. Greetham, H. L. et al. Clostridium colicanis sp. nov., from canine faeces. Int. J. Syst. Evol. Microbiol. 53, 259-262, https://doi.org/10.1099/ijs.0.02260-0 (2003).
30. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq. 2. Genome Biol. 15, 550, https://doi.org/10.1186/s13059-014-0550-8 (2014).
31. Conrads, G., Citron, D. M., Mutters, R., Jang, S. & Goldstein, E. J. Fusobacterium canifelinum sp. nov., from the oral cavity of cats and dogs. Syst. Appl. Microbiol. 27, 407-413, https://doi.org/10.1078/0723202041438509 (2004).
32. Selle, K. & Klaenhammer, T. R. Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health. FEMS Microbiol. Rev. 37, 915-935, https://doi.org/10.1111/1574-6976.12021 (2013).
33. Liu, Y., Fatheree, N. Y., Mangalat, N. & Rhoads, J. M. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G1087-1096, https://doi.org/10.1152/ajpgi.00124.2010 (2010).
34. Mackos, A. R., Eubank, T. D., Parry, N. M. & Bailey, M. T. Probiotic Lactobacillus reuteri attenuates the stressor-enhanced severity of Citrobacter rodentium infection. Infect. Immun. 81, 3253-3263, https://doi.org/10.1128/IAI.00278-13 (2013).
35. Frandsen, E. V., Poulsen, K. & Kilian, M. Confirmation of the species Prevotella intermedia and Prevotella nigrescens. Int. J. Syst. Bacteriol. 45, 429-435, https://doi.org/10.1099/00207713-45-3-429 (1995).
36. Yang, N. Y., Zhang, Q., Li, J. L., Yang, S. H. & Shi, Q. Progression of periodontal inflammation in adolescents is associated with increased number of Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythensis, and Fusobacterium nucleatum. Int. J. Paediatr. Dent. 24, 226-233, https://doi.org/10.1111/ipd.12065 (2014).
37. Sato, T. & Nakazawa, F. Coaggregation between Prevotella oris and Porphyromonas gingivalis. J. Microbiol. Immunol. Infect. 47, 182-186, https://doi.org/10.1016/j.jmii.2012.09.005 (2014).
38. Dicksved, J. et al. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J. Med. Microbiol. 58, 509-516, https://doi.org/10.1099/jmm.0.007302-0 (2009).
39. Sohn, S. H. et al. Analysis of gastric body microbiota by pyrosequencing: possible role of bacteria other than Helicobacter pylori in the gastric carcinogenesis. J. Cancer Prev. 82, 115-125, https://doi.org/10.15430/JCP.2017.22.2.115 (2017).
40. Li, T. H. et al. Alterations in gastric microbiota after H. Pylori eradication and in different histological stages of gastric carcinogenesis. Sci. Rep. 7, https://doi.org/10.1038/srep44935 (2017).
41. Yu, G. et al. Molecular characterization of the human stomach microbiota in gastric cancer patients. Front. Cell Infect. Microbiol. 6, 302, https://doi.org/10.3389/fcimb.2017.00302 (2017).
42. Coker, O. O. et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut, https://doi.org/10.1136/gutjnl-2017-314281 (2017).
43. Bashir, A., Miskeen, A. Y., Bhat, A., Fazili, K. M. & Ganai, B. A. Fusobacterium nucleatum: An emerging bug in colorectal tumorigenesis. Eur. J. Cancer. Prev. 24, 373-385, https://doi.org/10.1097/CEJ.0000000000000116 (2015).
44. Coppenhagen-Glazer, S. et al. Fap2 of Fusobacterium nucleatum is a galactose-inhibitable adhesin involved in coaggregation, cell adhesion, and preterm birth. Infect. Immun. 83, 1104-1113, https://doi.org/10.1128/IAI.02838-14 (2015).
45. Abed, J. et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe 20, 215-225, https://doi.org/10.1016/j.chom.2016.07.006 (2016).
46. Wong, S. H. et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut, https://doi.org/10.1136/gutjnl-2016-312766 (2016).
47. Poehlein, A., Schilling, T., BhaskarSathya Narayanan, U. & Daniel, R. First insights into the draft genome of Clostridium colicanis DSM 13634, isolated from canine feces. Genome Announc. 4, https://doi.org/10.1128/genomeA.00385-16 (2016).
48. Sanchez, B. et al. Probiotics, gut microbiota, and their influence on host health and disease. Mol. Nutr. Food Res. 61, https://doi.org/10.1002/mnfr.201600240 (2017).